Skip to content

Edgewise Therapeutics, Inc. EWTX Change in Lease Liabilities

Change in Lease Liabilities at other companies

Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-$106K-9.3%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$139K-7.8%
Scholar Rock logo
Scholar RockSRRK
-$1.44M+8.6%
Moderna logo
ModernaMRNA
-$7M-40.0%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s change in lease liabilities?
Edgewise Therapeutics, Inc. (EWTX) reported change in lease liabilities of -$196K in Q1 2026.
How has Edgewise Therapeutics, Inc.'s change in lease liabilities changed year-over-year?
Edgewise Therapeutics, Inc.'s change in lease liabilities decreased by 9.5% year-over-year, from -$179K to -$196K.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.